Fig. 1.
Fig. 2.
Fig. 3.
Evolution of Pseudomonas Aeruginosa susceptibility testing_
| Antibiogram | CSF (day 25) | BRS (day 25) | BRS (day 48) |
|---|---|---|---|
| Piperacillin-tazobactam | R | R | R |
| Amikacin | - | - | - |
| Aztreonam | R | R | R |
| Cefepime | R | R | SIE |
| Ceftazidime | R | R | R |
| Ciprofloxacin | R | R | R |
| Imipenem | R | R | R |
| Meropenem | R | R | R (>32 mg/l) |
| Tobramycin | S | S | S |
| Levofloxacin | R | R | R |
| Colistin | S | S (1.0 mg/l) | S (2.0 mg/l) |
| Ceftazidime-avibactam | R | R | R (>256 mg/l) |
| Ceftolozane-tazobactam | S | S | R |
| Imipenem-cilastin-relebactam | R (6.0 mg/l) | R | R (4.0 mg/l) |
| Meropenem-varobactam | - | - | - |